Sam Cobb, managing director and CEO of Australian biotech AdAlta Ltd., talks to Scrip senior writer Lucie Ellis about the company’s recent public listing and clinical development plans for lead product, AD-114, in idiopathic pulmonary fibrosis.
AdAlta CEO On Shark Antibody Technology
AdAlta CEO Sam Cobb discusses development of the company's novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.
More from Start-Ups & SMEs
More from Business
• By
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
• By
Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.
• By
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.